Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2026)

Akebia Therapeutics (AKBA) has 8 years of Non-Current Debt data on file, last reported at $36.4 million in Q1 2026.

• On a quarterly basis, Non-Current Debt fell 21.75% year-over-year to $36.4 million in Q1 2026; TTM through Mar 2026 was $36.4 million, a 21.75% decrease from a year earlier, with the FY2025 full-year figure at $48.2 million, up 24.7% from the prior year.
• Non-Current Debt for Q1 2026 stood at $36.4 million, down from $48.2 million in the prior quarter.
• Over the last five years, Non-Current Debt for AKBA reached as high as $98.2 million in Q2 2022 and fell as low as $17.2 million in Q4 2023.
• Historically, Non-Current Debt has averaged $41.6 million across 5 years, with a median of $38.2 million in 2024.
• Across the five-year window, Non-Current Debt sank 81.17% in 2023 and soared 125.18% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $34.1 million in 2022, then plunged by 49.58% to $17.2 million in 2023, then jumped by 125.18% to $38.7 million in 2024, then advanced by 24.7% to $48.2 million in 2025, then declined by 24.57% to $36.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $36.4 million in Q1 2026, $48.2 million in Q4 2025, and $47.6 million in Q3 2025.